Home > R&D > Research field > CRM197

CRM197

Many antigens are used as conjugates or conjugated vaccines because they have low immunogenicity, especially in infants, unless they are chemically linked to proteins. CRM197 is non-toxic at the genetic level and possesses a large complement of lysine that serve as advantages in conjugation. There are also studies showing that there is little carrier-induced immunosuppression inhibition compared to tetanus toxoid.

Using our proprietary technology, CRM197 was successfully produced in E. coli and purified with high yield. In our company, we keep searching its additional applications other than vaccine adjuvant of polysaccharide vaccines.

Development progress : CRM197

Development Nonclinical Clinical Item approval Sale
CRM197 2016 ~ 2018 2018 ~ 2019 2019 ~ 2023 2023 ~ 2024 2024 ~